📜 Post with us on Reddit
📝 Create a new article
🏭 Create a company page
🇬🇧 - in English
🇫🇷 - en Français (FR)
🇵🇹 - em Português (PT)
🇩🇪 - auf Deutsch (DE)
🇯🇵 - 日本語で (JA)
Sponsored articles

You can edit almost every page by Creating an account and confirming your email.

Cytiva

From EverybodyWiki Bios & Wiki


Cytiva
Cytiva
Subsidiary of Danaher Corporation
ISIN🆔
Founded 📆
Founder 👔
Area served 🗺️
Members16000 (2023)
Number of employees
🌐 Websitecytiva.com
📇 Address
📞 telephone

Cytiva is a global provider of technologies and services related to the development, manufacture, and delivery of vaccines, diagnostics, and therapeutics to customers in organizations including academia, biotechnology, and drug manufacturing.[1][2][3] The Cytiva name stems from 'cyto' meaning 'cell' in Greek, and 'iva' a Latin suffix meaning 'doing' and 'capable of'.[4]

As of May 2023, Cytiva employed more than 16,000 associates in over 40 countries.[5]

History

Whatman

  • In 1733, James Whatman invented a new way to manufacture paper using a weaving method.[6] This method created a paper stronger than ‘laid’ paper, making it suitable for later scientific applications.[7]
  • In 2008, GE Healthcare acquired Whatman for $713 million, providing GE Healthcare with a “portfolio of filters and membranes for laboratory, research, life sciences, and medical technology applications.”[8]

1980–2009

Pharmacia, Amersham, and GE Healthcare

  • In 1982, Pharmacia Fine Chemicals, a small Stockholm-based biotechnology company, developed fast protein liquid chromatography (FPLC).[9]
  • In 1986, Pharmacia Fine Chemicals brand name became Pharmacia Biotech.[10]
  • In 1995, through a series of mergers and acquisitions during the 1990s, Pharmacia Biotech became part of Pharmacia & Upjohn.[11]
  • In 1996, the ÄKTA™ Explorer was launched by Pharmacia Biotech, enabling scientists to carry out FPLC for protein research.[9]
  • In 1997, Pharmacia Biotech merged with Amersham Life Science to become Amersham Pharmacia Biotech.[12][13][14]
  • In 1999, Amersham Pharmacia Biotech acquired Molecular Devices for $256 million.[15][16]
  • In 2000, Amersham Pharmacia Biotech developed a high-throughput genome sequencing technology which was used for part of the mapping conducted by the Human Genome Project.[17] This sequencing is a form of bioinformatics and identifies genes and other features in a raw DNA sequence, known as genome annotation. The Joint Genome Institute (JGI) Production Sequencing Facility noted that it "[used] 84 new high-throughput MegaBACE DNA sequencing machines acquired from Amersham Pharmacia Biotech. These machines use[d] multiple thin "capillary" tubes instead of large flat gels to separate and "read" the DNA sequence. The technology was developed largely with funding from the DOE Human Genome Program and licensed to AP Biotech.”[18]
  • In 2001, Amersham Biosciences introduced a resin designed to improve resin functionalities throughout monoclonal antibody purification (also known as MABs).[19] As noted by Digamber Singh Chahar, Selvan Ravindran, S.S. Pisal "monoclonal antibody purification involves selective isolation of antibodies from resin to obtain both a high purity level and a high-density perfusion cell culture."[20]
  • In 2002, Pharmacia sold its share of Amersham Pharmacia Biotech to Amersham Plc, which was renamed to Amersham Biosciences.[21][22][23]
  • In 2004, General Electric acquired Amersham Biosciences for $9.5 billion and combined with GE Medical Systems to create GE Healthcare.[24][25][26]

Biacore

  • In 1990, the first Biacore instrument, based on the principle of Surface Plasmon Resonance (SPR), was launched by Pharmacia Biosensor, a life sciences company founded by Pharmacia.[27] SPR is a technique used to measure molecular interactions in real time. Primarily an instrument used to screen molecules for drug discovery, SPR principles are now accompanied by software incorporating Artificial Intelligence.[28]
  • In 2006, GE Healthcare acquired Biacore for $390 million.[29][30] The acquisition broadened the company’s offering of tools for protein research.

Wave Biotech

  • In 2002, the WAVE bioreactor 200 was launched by WAVE biotech, a US-based supplier of disposable manufacturing technologies and processing equipment for the biopharmaceutical industry.[31] The design was first patented by Dr. Vijay Singh and involved a disposable cultivation bag supported on a rocking platform to facilitate cell expansion.[32]
  • In 2007, WAVE biotech was acquired into the life sciences portfolio of GE Healthcare.[33][34]
  • In 2012, the WAVE bioreactor was used to grow engineered cells and identify the best conditions for each cell type, which contributed to the treatment of cancer with CAR T cell therapy.[35]

2010–2019

PAA Laboratories GmbH

  • In August 2011, GE Healthcare acquired PAA Laboratories GmbH, which developed and supplied cell culture media for biomedical research and the biopharmaceutical and vaccine manufacturing industry.[36] The acquisition allowed GE Healthcare to “expand its offering of products and services for cell biology research and for the discovery and manufacture of biopharmaceuticals including recombinant proteins, antibodies and vaccines.”[37]

Xcellerex, Inc.

  • In 2012, GE Healthcare acquired Xcellerex, Inc., a supplier of innovative manufacturing technologies for the biopharmaceutical industry.[38] The acquisition expanded “GE Healthcare’s offering of technologies and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines, a key area of growth for the company.”[39]

Biosafe Group

  • In 2013, GE Heathcare acquired Biosafe Group, which supplies integrated cell bioprocessing systems for the cell therapy and regenerative medicine industry.[40][41] The acquisition expanded GE Healthcare’s reach to several new cell and therapy types.[42]

Thermo Fisher Scientific Units

  • In 1967, Dr. Rex Spendlove, a Utah State University professor, conducted foundational research leading to the development of cell culture media which could be used in bioprocessing to grow and cultivate cells.[43]
  • In 2014, GE Healthcare acquired three Thermo Fisher Scientific units for $1.1 billion.[44] The three business units included HyClone (cell culture media and sera), Sera-Mag (magnetic beads), and Dharmacon (gene modulation tools).[45] The acquisition “helped the company expand its presence in protein analysis and medical diagnostics.”[46]

Asymptote

  • In 2017, GE Healthcare acquired Asymptote, a company specializing in cryochain technology for sensitive cellular therapies.[47][48] The acquisition strengthened GE Healthcare’s cell therapy portfolio including enabling the cryopreservation of cellular materials.[49]

2020–present

Danaher Corporation

  • In March 2020, Danaher Corporation acquired GE Healthcare Life Sciences for $21.4 billion.[50] The company name was subsequently changed to Cytiva, and sits under Danaher Corporation’s Life Sciences platform.[51]
  • In July 2021, Cytiva and its fellow Danaher operating company, Pall Corporation, announced the investment of $1.5 billion over two years to meet the growing demand for biotechnology solutions.[52] This plan has resulted in the opening of a new manufacturing site in Cardiff, Wales.[53] Additional plans include increasing manufacturing capacity in existing sites, such as the doubling of cell culture media production in Pasching, Austria which is expected to come online in 2023.[54]

Vanrx Pharmasystems

  • In 2021, Cytiva acquired Vanrx Pharmasystems which develops robotic aseptic filling machines to fill vials, syringes, and cartridges.[55][56] This acquisition was designed to broaden Cytiva’s manufacturing capacity solutions, focusing on the fill step before distribution to patients.[55]

GoSilico

  • In 2021, Cytiva acquired GoSilico, adding a portfolio of scientific software based on mechanistic modeling for use in bioprocessing functions and downstream processes.[57]

Intermountain Life Sciences

  • In 2021, Cytiva acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell-culture media.[58][59] The acquisition complements Cytiva’s cell culture media portfolio and will boost its annual production capacity by millions of liters.[60]

Pall Life Sciences

  • In September 2022, it was announced that Pall Life Sciences will be merging with Cytiva to create a new Biotechnology Group within Danaher. The merger was completed in May 2023.[61][62][63] As of May 2023, Cytiva employed more than 16,000 associates in over 40 countries.[64]

Products and services

The organization operates within the life sciences segment and provides technology and services to the following areas: aseptic filling,[65] automation,[66] bioprocessing filtration technology,[67] cell culture products,[68] cell therapy technologies,[69] chromatography,[70] laboratory supplies,[71] molecular biology and biochemistry,[50] protein analysis equipment and supplies,[72] service plans,[19] training,[73] and filters for both laboratory and industrial use,[74] membranes and devices.[66]

Collaborations

In 2016, GE Healthcare, along with the Centre for Commercialization of Regenerative Medicine (CCRM) and the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), established the Centre for Advanced Therapeutic Cell Technologies (CATCT) in Toronto, Canada.[75] The center was established to “accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies.”[76]

In 2018, along with the Swedish government, Cytiva co-founded the Testa Center which serves as a "testbed" to help find new ways to support academia, the bioprocess industry, and emerging biotech.[77] It is a facility used to strategically pin-point bioprocessing areas of importance by the Swedish government. It was designed to be an open-access bioprocessing testbed with modern upscaling equipment and “to promote the life science sector’s growth and bridge the gap between discovery and industrialization”.[77]

In 2019, Cytiva began to work with the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. According to NIBRT, this was to help them “keep pace with changing modalities and technologies by providing training for the next generation of talent within the biomanufacturing industry.”[78] Cytiva is also a co-founder of the Landmark Bio Initiative and has committed to contribute products and technologies and help with training of staff.[79]

In 2020, Cytiva published the Global Biopharma Resilience Index, a report on the state of the biopharmaceutical industry conducted with Longitude (the Financial Times’ research group).[80][81] Analysis of survey responses from 1,100 industry experts found five prevailing issues: the availability of a skilled workforce, supply-chain resilience, strength of the R&D ecosystem, quality and agility of manufacturing processes, and the effectiveness of government policy in supporting the industry.[82][83] In 2023, Cytiva released a new index which found that the overall resilience of the index had dropped from 6.08 out of ten compared to 6.6 in 2021; this drop was credited to a lack of confidence in the R&D ecosystem and a general dissatisfaction with government policy and regulation.[84]

References

  1. ↑ "Cytiva to provide bioprocessing training at Indian incubation centre". cleanroomtechnology.com. 2022-06-20.
  2. ↑ "BBC collaborates with Cytiva to aid in bioprocessing training programme". biospectrumindia.com. Retrieved 2022-10-06.
  3. ↑ "Cytiva". TECHNIA (US). Retrieved 2022-10-06.
  4. ↑ "GE Healthcare Life Sciences rebrands to 'Cytiva'". ATMP Sweden. Retrieved 2022-06-17.
  5. ↑ Sterling, John (2023-05-02). "Merger of Cytiva and Pall's Life Sciences Business Now Complete". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-09-04.
  6. ↑ "J WHATMAN - THE MASTER OF WESTERN PAPERMAKING". Vintage Paper Co. Retrieved 2022-10-06.
  7. ↑ "Whatman Paper Division". Analytical Chemistry. 52 (6): 644A. 1980-05-01. doi:10.1021/ac50056a751. ISSN 0003-2700.
  8. ↑ "GE Healthcare to Acquire Whatman for $713M". GenomeWeb. 2008-02-04. Retrieved 2022-10-06.
  9. ↑ 9.0 9.1 Madadlou, Ashkan; O’Sullivan, Siobhan; Sheehan, David (2011), Walls, Dermot; Loughran, Sinéad T., eds., "Fast Protein Liquid Chromatography", Protein Chromatography: Methods and Protocols, Methods in Molecular Biology, Totowa, NJ: Humana Press, 681, pp. 439–447, doi:10.1007/978-1-60761-913-0_25, ISBN 978-1-60761-913-0, PMID 20978981, retrieved 2022-10-20
  10. ↑ Waluszewski, Alexandra (2004-03-01). "A competing or co-operating cluster or seven decades of combinatory resources? What's behind a prospering biotech valley?". Scandinavian Journal of Management. Different Perspectives on Competition and Cooperation. 20 (1): 125–150. doi:10.1016/j.scaman.2004.05.002. ISSN 0956-5221.
  11. ↑ "Pharmacia Merger | Pfizer". www.pfizer.com. Retrieved 2022-10-20.
  12. ↑ "Pharmacia Biotech | Science Museum Group Collection". collection.sciencemuseumgroup.org.uk. Retrieved 2022-10-06.
  13. ↑ "Amersham close to life sciences merger". The Independent. 1997-05-30. Retrieved 2022-10-06.
  14. ↑ Journal, Stephen D. MooreSpecial to The Wall Street (1997-06-11). "Amersham Merges Division With Pharmacia & Upjohn". Wall Street Journal. ISSN 0099-9660. Retrieved 2022-10-06.
  15. ↑ Reuters (1998-08-11). "COMPANY NEWS; NYCOMED JOINT VENTURE TO ACQUIRE MOLECULAR DYNAMICS". The New York Times. ISSN 0362-4331. Retrieved 2022-10-20.
  16. ↑ Biomedtracker (13 Jul 1999). "Amersham Pharmacia acquires Molecular Dynamics for $256mm". Scrip Informa Pharma Intelligence. Retrieved 2022-08-26.
  17. ↑ "About the Human Genome Project". web.ornl.gov. Retrieved 2022-10-06.
  18. ↑ "Human Genome News Vol.10, No.3-4, October 1999". web.ornl.gov. Retrieved 2022-10-06.
  19. ↑ 19.0 19.1 Philippidis, Alex (2020-01-01). "Cytiva Picks Up Where GE Leaves Off after $21B Deal". GEN Edge. 2 (1): 132–136. doi:10.1089/genedge.2.1.25. Unknown parameter |s2cid= ignored (help)
  20. ↑ Chahar, Digamber Singh; Ravindran, Selvan; Pisal, S. S. (2020-01-01). "Monoclonal antibody purification and its progression to commercial scale". Biologicals. 63: 1–13. doi:10.1016/j.biologicals.2019.09.007. ISSN 1045-1056. PMID 31558429. Unknown parameter |s2cid= ignored (help)
  21. ↑ "Pharmacia Corp selling stake in Amersham Biosciences for $1 billion -". www.thepharmaletter.com. Retrieved 2022-10-06.
  22. ↑ "Amersham buys out bioscience ally". The Guardian. 2002-03-13. Retrieved 2022-10-06.
  23. ↑ Kitson, Sean L. (2007). "Amersham radiochemistry to GE Healthcare". Journal of Labelled Compounds and Radiopharmaceuticals. 50 (9–10): 737–745. doi:10.1002/jlcr.1427.
  24. ↑ Gilpin, Kenneth N. (2003-10-10). "G.E. to Buy British Medical Company for $9.5 Billion in Stock". The New York Times. ISSN 0362-4331. Retrieved 2022-10-20.
  25. ↑ "GE completes acquisition of Amersham, restructures GE Healthcare". www.bizjournals.com. 2004-04-08. Retrieved 2022-10-06.
  26. ↑ "General Electric acquires UK medical technology company Amersham for US$9.5 billion". Membrane Technology. 2003 (12): 1. 2003-12-01. doi:10.1016/S0958-2118(03)00001-6. ISSN 0958-2118.
  27. ↑ Gaudreault, Jimmy; Forest-Nault, Catherine; De Crescenzo, Gregory; Durocher, Yves; Henry, Olivier (November 2021). "On the Use of Surface Plasmon Resonance-Based Biosensors for Advanced Bioprocess Monitoring". Processes. 9 (11): 1996. doi:10.3390/pr9111996. ISSN 2227-9717.
  28. ↑ "BIACORE INTELLIGENT ANALYSIS SOFTWARE Trademark of Cytiva Sweden AB - Serial Number 97166548 - Alter". alter.com. Retrieved 2022-10-06.
  29. ↑ Guha, Malini. "GE agrees to purchase Biacore for $390m". Financial Times.
  30. ↑ "GE Healthcare to Acquire Biacore for $390M". GenomeWeb. 2006-06-20. Retrieved 2022-10-17.
  31. ↑ Mikola, Mark; Seto, Jennifer; Amanullah, Ashraf (2007-07-01). "Evaluation of a novel Wave Bioreactor® cellbag for aerobic yeast cultivation". Bioprocess and Biosystems Engineering. 30 (4): 231–241. doi:10.1007/s00449-007-0119-y. ISSN 1615-7605. PMID 17340094. Unknown parameter |s2cid= ignored (help)
  32. ↑ Ladage, KshitiJ (TJ). "Bioreactor Preferences from an Outsourcing Perspective – Part I". www.pharmasalmanac.com. Retrieved 2022-10-06.
  33. ↑ "GE Healthcare Acquires Wave Biotech". PharmTech. Retrieved 2022-10-06.
  34. ↑ "GE Healthcare buys Wave Biotech". The Engineer. Retrieved 2022-10-06.
  35. ↑ Stroncek, David F.; Berger, Carolina; Cheever, Martin A.; Childs, Richard W.; Dudley, Mark E.; Flynn, Peter; Gattinoni, Luca; Heath, James R.; Kalos, Michael; Marincola, Francesco M.; Miller, Jeffrey S.; Mostoslavsky, Gustavo; Powell, Daniel J.; Rao, Mahendra; Restifo, Nicholas P. (2012-03-15). "New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer". Journal of Translational Medicine. 10 (1): 48. doi:10.1186/1479-5876-10-48. ISSN 1479-5876. PMC 3362772. PMID 22420641.
  36. ↑ "GE Healthcare to acquire PAA Laboratories GmbH, broadening capabilities in growing biopharmaceutical manufacture segment". Manufacturing.net. 2011-08-16. Retrieved 2022-10-20.
  37. ↑ "GE Healthcare to Acquire PAA Laboratories GmbH, Broadening Capabilities in Growing Biopharmaceutical Manufacture Segment". www.businesswire.com. 2011-08-16. Retrieved 2022-10-06.
  38. ↑ Writer, GEN Staff (2012-03-07). "GE Healthcare to Snag Xcellerex for Single-Use Manufacturing Technology". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  39. ↑ PhD, Angelo DePalma (2012-11-15). "GE Healthcare Improves Single-Use Abilities". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  40. ↑ Writer, GEN Staff (2016-07-13). "GE Healthcare Acquires the Biosafe Group". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  41. ↑ "GE Healthcare Acquire Biosafe". Biopharma from Technology Networks. Retrieved 2022-10-20.
  42. ↑ Writer, GEN Staff (2016-07-13). "GE Healthcare Acquires the Biosafe Group". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  43. ↑ BioUtah. "BioUtah Announces 2021 BioUtah Life Sciences Awards to be Presented at the Virtual Renalytix BioHive Summit". www.prnewswire.com. Retrieved 2022-10-06.
  44. ↑ Dish, The (2014-03-25). "GE Healthcare Completes Acquisition of Three Thermo Fisher Scientific Business Divisions". Cell Culture Dish. Retrieved 2022-10-17.
  45. ↑ Writer, GEN Staff (2014-01-06). "GE Healthcare Acquiring Thermo Businesses". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-17.
  46. ↑ Wasserman, Emily (2014-03-24). "GE finalizes $1B Thermo Fisher Scientific deal, snatches up 3 business units". Fierce Biotech. Retrieved 2022-10-06.
  47. ↑ "GE Healthcare acquires Asymptote | Cambridge Network". www.cambridgenetwork.co.uk. Retrieved 2022-10-20.
  48. ↑ "GE Healthcare Acquires Asymptote For Complete, Digitally-Enabled Cryogenic Cold Chain Technology Supporting Safe Manufacture And Delivery Of Cellular Therapies". BioSpace. Retrieved 2022-10-20.
  49. ↑ Writer, GEN Staff (2017-04-11). "GE Healthcare Adds to Its Cell Therapy Portfolio by Acquiring Asymptote". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  50. ↑ 50.0 50.1 Stanton, Dan (2020-04-01). "Cytiva rises as Danaher completes $21bn deal - Bioprocess Insider". BioProcess International. Retrieved 2022-10-17.
  51. ↑ biopharma-reporter.com. "GE Healthcare Life Sciences completes transition into Cytiva". biopharma-reporter.com. Retrieved 2022-10-20.
  52. ↑ "Pall & Cytiva invest $1.5bn to expand manufacturing capacity for biotech customers". European Pharmaceutical Manufacturer. 2021-07-27. Retrieved 2022-10-17.
  53. ↑ "Cytiva opens doors at Cardiff site as part of $1.5B global expansion". Endpoints News. Retrieved 2022-10-06.
  54. ↑ Radinger, Fritz (2022-02-05). "Cytiva verdoppelt ab 2023 die Produktion von Zellkulturmedien am österreichischen Standort in Pasching". Fritz Radinger PR. Retrieved 2022-10-06.
  55. ↑ 55.0 55.1 Sterling, John (2021-02-04). "Cytiva Acquires Aseptic Filling Firm Vanrx Pharmasystems". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  56. ↑ "Cytiva acquires Canadian aseptic filling innovator Vanrx". www.cleanroomtechnology.com. Retrieved 2022-10-20.
  57. ↑ Stanton, Dan (2021-06-04). "Cytiva looks to mechanistic modeling in GoSilico deal - Bioprocess Insider". BioProcess International. Retrieved 2022-10-20.
  58. ↑ "Cytiva Acquires Intermountain Life Sciences". BioPharm International. Retrieved 2022-10-20.
  59. ↑ Sterling, John (2021-07-01). "Cytiva Acquires Intermountain Life Sciences". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  60. ↑ "Cytiva Acquires Intermountain Life Sciences". BioPharm International. Retrieved 2022-10-20.
  61. ↑ Stanton, Dan (2022-09-22). "Danaher merging Cytiva and Pall - BioProcess Insider". BioProcess International. Retrieved 2023-09-04.
  62. ↑ Stanton, Dan (2023-05-02). "Danaher completes Cytiva Pall merger - BioProcess Insider". BioProcess International. Retrieved 2023-09-04.
  63. ↑ "Cytiva and Pall Life Sciences complete integration to create a global innovation and solutions leader in biotechnology". Cytiva. Retrieved 2023-09-04.
  64. ↑ Sterling, John (2023-05-02). "Merger of Cytiva and Pall's Life Sciences Business Now Complete". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-09-04.
  65. ↑ Iyer. "Biomedical advances in the treatment of COVID-19: An Indo-Canadian perspective". www.ijncd.org. Retrieved 2022-10-06.
  66. ↑ 66.0 66.1 Sterling, John (2022-05-11). "Automating Bioprocessing from Consumables to Cleaning". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-06.
  67. ↑ May, Mike (2020-07-01). "Debottlenecking Opportunities Clearer with a Bioprocessing 4.0 Perspective". Genetic Engineering & Biotechnology News. 40 (7): 32–33, 36. doi:10.1089/gen.40.07.09. ISSN 1935-472X. Unknown parameter |s2cid= ignored (help)
  68. ↑ Roquemore, Liz; Kauss, M. Ariel; Hather, Catherine; Thomas, Nick; Uppal, Hirdesh (2017), Clements, Mike; Roquemore, Liz, eds., "In Vitro Cardiotoxicity Investigation Using High Content Analysis and Human Stem Cell-Derived Models", Stem Cell-Derived Models in Toxicology, Methods in Pharmacology and Toxicology, New York, NY: Springer, pp. 247–269, doi:10.1007/978-1-4939-6661-5_13, ISBN 978-1-4939-6661-5, retrieved 2022-10-06
  69. ↑ Algorri, Marquerita; Abernathy, Michael J.; Cauchon, Nina S.; Christian, Twinkle R.; Lamm, Celeste Frankenfeld; Moore, Christine M. V. (2022-03-01). "Re-Envisioning Pharmaceutical Manufacturing: Increasing Agility for Global Patient Access". Journal of Pharmaceutical Sciences. 111 (3): 593–607. doi:10.1016/j.xphs.2021.08.032. ISSN 0022-3549. PMID 34478754 Check |pmid= value (help). Unknown parameter |s2cid= ignored (help)
  70. ↑ Vuksanaj, Kathy (2022-05-02). "Chromatography Accommodates New Biopharmaceutical Modalities". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-06.
  71. ↑ "Cytiva Helps Improve Patient Outcomes by Delivering the Right Products at the Right Time". Salesforce.com. Retrieved 2022-10-06.
  72. ↑ Bellone, Maria Laura; Puglisi, Andrea; Dal Piaz, Fabrizio; Hochkoeppler, Alejandro (2021-06-18). "Production in Escherichia coli of recombinant COVID-19 spike protein fragments fused to CRM197". Biochemical and Biophysical Research Communications. 558: 79–85. doi:10.1016/j.bbrc.2021.04.056. ISSN 0006-291X. PMC 8057744 Check |pmc= value (help). PMID 33906110 Check |pmid= value (help).
  73. ↑ Nelson, Millie (2022-08-31). "Cytiva and ForecyteBio partner to advance CGTs - BioProcess Insider". BioProcess International. Retrieved 2022-10-17.
  74. ↑ "Whatman™ Filters for Water, Air and Soil Testing". VWR. Retrieved 2022-10-06.
  75. ↑ PhD, Julianna LeMieux (2019-01-31). "GE Healthcare Looks to Spawn Growth in Regenerative Medicine with CCRM Partnership". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-10-20.
  76. ↑ kitchens-led-centre-solve-cell-therapy "GE Healthcare, FedDev Ontario commit CAD $40M for new CCRM-led centre to solve cell therapy manufacturing challenges | GE News" Check |url= value (help). www.ge.com. Retrieved 2022-10-20.
  77. ↑ 77.0 77.1 "Testa Center". STUNS Life science (in svenska). Retrieved 2022-10-06.
  78. ↑ Quinn, Alison (2021-05-19). "Cytiva eLearning catalogue now available on the NIBRT Online Academy". National Institute for Bioprocessing Research. Retrieved 2022-10-06.
  79. ↑ "Landmark Bio, a biomanufacturing facility co-founded by MIT, breaks ground in Watertown Arsenal". MIT News | Massachusetts Institute of Technology. Retrieved 2022-10-06.
  80. ↑ "Cytiva: Global Biopharma Resilience Index". FT Longitude. Retrieved 2022-10-06.
  81. ↑ BIA. "Cytiva and Longitude - a Financial Times company - reveal five major challenges for the industry in new Global Biopharma Resilience Index". www.bioindustry.org. Retrieved 2022-10-17.
  82. ↑ longitude. "The Global Biopharma Resilience Index". www.ft.com. Retrieved 2022-10-06.
  83. ↑ Koul, Rahul (2021-03-10). "New 'Global Biopharma Resilience Index' lists 5 major challenges for the industry". BioVoiceNews. Retrieved 2022-10-06.
  84. ↑ Stanton, Dan (2023-06-09). "Biopharma resilience: Supply chain improving but talent gap grows, Cytiva - BioProcess Insider". BioProcess International. Retrieved 2023-09-04.

External links


This article "Cytiva" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Cytiva. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.


Retrieved from "https://en.everybodywiki.com/index.php?title=Cytiva&oldid=6119416"
License CC BY-SA 3.0
Powered by MediaWiki